Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “STL303 arm participants will receive a specific dose of STL303”In the company’s words, NCT07606352 on ClinicalTrials.gov
- Tested for
- IgAN, Geographic Atrophy
- Main trialPhase 2
- “This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients. About 15 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of STL303 or placebo capsules orally according to protocol.”In the company’s words, NCT07606352 on ClinicalTrials.gov
Other drugs for IgAN
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up2
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jul 2027 | Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy | |
| Phase 2Recruiting | Jul 2028 | A Study in Adults With Geographic Atrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026